HQ AFOSI COLLECTION REQUIREMENT 50 (HQ CR 50)

• Document Type: CREST
• Collection: General CIA Records
• Document Number (FOIA) /ESDN (CREST): CIA-RDP83M00171R001500010012-8
• Release Decision: RIFPUB
• Original Classification: K
• Document Page Count: 6
• Document Creation Date: December 20, 2016
• Document Release Date: March 6, 2006
• Sequence Number: 12
• Publication Date: September 7, 1979
• Content Type: LETTER

REPLY TO
ATTN OFt
Approved For Release 2007/03/09 : CIA-RDP83M00171R0015000fd0'12.
DEPARTMENT OF THE AIR FORCE
HEADQUARTERS AIR FORCE OFFICE OF SPECIAL INVESTIGATIONS
WASHINGTON, DC 20314
HQ AFOSI Collection Requirement 50 (HQ CR 50)
All AFOSI USAFE Dists, Dets, and RAs (CAT VII)
1. Purpose. The purpose of this letter is to introduce HQ CR 50 which targets
drug availability and drug trafficking in the USAFE Theater.
2. Concept and Application. This CR reduces a concept to practical
application and, as such, is a test of the concept. The concept addresses two
needs. One need is to develop an effective vehicle for reporting local drug
availability information to local USAF users, including commanders and
DAACCs. The other need is to develop a method for systematically collecting
information concerning drug trafficking techniques which indicate direct USAF
involvement; therefore, merit direct AFOSI interest and action. The CR
describes the use of two new AFOSI Forms, 161 and 165, which are the formats
you will use to collect and report responsive information from the local level.
3. AFOSI Form 161. Crime Information Report 79-1, "Computing and
Reporting Drug Seizures" and the USAFE "Counterpush" experience focused the
need for AFOSI Form 161, "AFOSI Illicit Drug Market Assessment." AFOSI
units need the information to conduct offensive investigative activities and to
prepare meaningful Reports of Investigation. Command needs the data to
better assess their local problem. Additionally, the data is collected in a
format which will permit multiple levels of analysis and is suitable for eventual
computerization. Unfortunately, this form contains two typographical errors
which should be corrected locally prior to dissemination. On the front side
under "Drug Type" the word "heroin" is mispelled (HEORIN). On the back side
under "Average Dosage Unit" the quantity for LSD should read "ug"
(micrograms) instead of "mg" (milligrams).
4. AFOSI Form 165. Case Type 456 and 17/0, as well as substantive case
files, focused the need for AFOSI Form 165, "AFOSI Report of Illicit Drug
Trafficking." Crime Special Study 79-9, "Air Force Drug Trafficking in USAFE"
pointed to the need for more sophisticated reporting formats in the important
area of drug trafficking. The format which was developed is designed to
generate significant and detailed data elements and to organize them in a way
that permits relatively simple collation. The purpose of this process is to
facilitate the exchange of information between districts and to
USAF review(s) completed.
Approved For Release 2007/03/09 : CIA-RDP$3M00171 R001500010012-8
 Approved For Release 2007/03/09 : CIA-RDP83M00171 R001500010012-8
produce reports, at HQ AFOSI, which will be sent back to the field in a form
that is more useful than the original input. Inasmuch as this feedback will
present the "big picture" it will enhance target selection and evidence
gathering, thereby substantially improving our interdiction efforts.
5. Test Application. The USAFE Theater was chosen to test the application
of this collections concept. "Counterpush" and the continuing high level
interest in that action plan, is a major reason for the selection. The
commendable AFOSI USAFE response to that plan suggests a test environment
that will provide a thorough evaluation of this application of a concept.
6. Evaluation. While IVG will be evaluating the responses to the CR at the
HQ AFOSI level, the bulk of the burden must rest with the agents, at all levels,
who work with the CR. Your comments, critiques, and suggestions will aid
immeasurably in helping us to refine the application of this concept and achieve
a workable methodology that can be used worldwide.
7. Forms Distribution. HQ AFOSI/DAP is making initial distribution of these
forms. Districts should initiate action to establish routine requirements for
them. Emergency supplies are available from HQ AFOSI/DAP.
8. HQ CR 47. HQ CR 50 suspends the operation of HQ CR 47 in USAFE for
the period of the HQ CR 50 suspense.
FOR THE COMMANDER
a i.
HUGH W. BARBER, Jr., Lt Col, USAF
Asst D'rector of Criminal Investigations
1 Atch
HQ CR 50
Cy to: AFOSI OL-G
HQ AFOSI/IVC
Approved For Release 2007/03/09 : CIA-RDP83M00171 R001500010012-8
 Approved For Release 2007/03/09 : CIA-ROP83M00171 ROO1500010012-8
DEPARTMENT OF THE AIR FORCE
HEADQUARTERS AIR FORCE OFFICE OF SPECIAL INVESTIGATIONS
WASHINGTON, DC 20314
REPLY TO IVG
ATTN OFi
Headquarters Collection Requirement 50 (HQ CR 50)
7 SEP 1979
All AFOSI USAFE Dists, Dets, and RAs (CAT VII)
1. TARGET. Drug Availability and Illicit Drug Trafficking in the USAFE
Theater.
2. BACKGROUND. CINCUSAFE has tasked AFOSI with significant
responsibility for the interdiction of drug trafficking in the USAFE theater.
Recent AFOSI investigations have again demonstrated that illicit trafficking is
an important aspect of the overall drug problem. This CR establishes a
systematic method for collecting, reporting and collating drug trafficking
information pertinent to the USAF. If conscientiously applied, it should be an
effective tool not only in assessing the extent of drug trafficking within USAFE,
but also in planning operations to thwart drug trafficking by USAF and
USAF-affiliated personnel. In some respects, the approach of this CR is
innovative, but its message is tested and proven -- the battle against drug abuse
must be fought above the user level. This CR targets trafficking by use of
USAF aircraft, and by USAF and USAF-affiliated personnel because that is
where AFOSI's mission responsibilities and investigative jurisdiction most
appropriately extend and where AFOSI has the greatest opportunity to interdict
the drug trade.
3. INTERROGATORIES:
a. Identify drugs being abused by USAF and USAF-affiliated personnel.
For each drug of abuse, provide:
(1) The weight/unit count, price and purity (where appropriate) of
the usual illicit retail (street) level sale.
(2) The weight/unit count, price and purity (where appropriate) of
the usual wholesale (dealer) level sale.
(3) An assessment concerning the local availability of the drug.
(4) When appropriate, amplifying remarks to explain unique factors
associated with the drug, i.e., statements regarding the legality of
over-the-counter dispensation in the local area; packaging data; street or slang
name; etc.
Approved For Release 2007/03/09 : CIA-RDP83M001.71 R001500010012-8
 Approved For Release 2007/03/09 : CIA-RDP83M00171 R001500010012-8
b. Report trafficking patterns relating to the planned, alleged or actual
use of USAF or USAF-contract aircraft in the illicit transport of drugs. In each
instance, provide:
(1) Date of incident.
(2) Type, quantity and value of drugs.
(3) Type of aircraft and its routing, to include point of origin,
interim stops, and destination. Indicate specific locations where drugs were
introduced onto and retrieved from the aircraft.
(4) Smuggling method (i.e., secreted in drogue chute, stored in
electrical panel, etc.); concealment technique (i.e., packaged in electrical tape,
sealed in tinfoil, etc.); and arrangment for retrieval/delivery of drugs.
(5) Subject identifying data, to include Air Force Specialty Code
(AFSC), grade, duty status during incident (i.e., permanent party (Perm Party),
TDY, LV, AFRes, ANG, etc.), permanent duty assignment location, and motive
(i.e., profit, favor, unwitting, etc.) NOTE: Complete as much of the subject
identifying data as possible if incident involves personnel of another US military
department, military dependents or civilians authorized to travel on USAF
aircraft.
(6) An evaluation of source and information.
(7) A reference to an AFOSI file number or source identification.
c. Report drug trafficking techniques planned, attempted or used by
USAF or USAF-affiliated personnel when the incidents involve other than
trafficking on USAF aircraft. In each instance, provide:
(1) Date of incident.
(2) Type, quantity and value of drugs.
(3) Conveyance used; for example, mail; household goods (HHG)
shipment; private, commercial or government auto (PA, CA, GA); private,
commercial or government rail (PR, CR or GR); private, commercial or
government bus (PB, CB or GB); private commercial or government vessel (PV,
CV, or GV); or private or commercial plane (PP or CP).
(4) Routing of the drug trafficker, smuggler or courier )J or the
drugs. Include point of origin, interim stops, destination, and location(s) where
drugs were stored, delivered or received.
Approved For Release 2007/03/09 : CIA-RDP83M00171 R001500010012-8 - i 11 11
 Approved For Release 2007/03/09 : CIA-RDP83M00171 R001500010012-8
. (5) Smuggling method (i.e., secreted in false bottom suitcase, taped
to body, etc.); concealment technique (i.e., wrapped in rubber sealant, hidden in
toothpaste tube, dissolved as a liquid etc.); and arrangements for retrieval or
delivery.
(6) Subject identifying data (see para 3b(5), above).
(7) An evaluation of source and information.
(8) A reference to an AFOSI file number or source identification.
4. SPECIAL INSTRUCTIONS.
a. Reporting Standards.
(1) Report weights and values of drugs in metric terms and U.S.
dollars, respectively.
(2) Do not include reports of seizures or arrests where the subject
is merely in possession of personal use quantities of drugs unless a particular
seizure is of local significance (e.g., new drug on the scene).
(3) Do not report unverified items from the press.
(4) Do not prepare a 456 when the information is non-specific and
obviously unverifiable. For example, unsubstantiated information to the effect
that USAF personnel are trafficking drugs between Turkey and Germany has no
value unless some detail can be reported concerning the type of drug, method of
trafficking or concealment, leads relating to the persons involved, etc. Do
follow-up, however, by local targeting for additional details, e.g., identities of
others who may have pertinent knowledge, enhanced "customs" inspections, etc.
(5) Do not use responses to this CR to circumvent or substitute for
established AFOSI operational reporting requirements.
b. Reporting Formats. The following procedures apply:
(1) Information responsive to interrogatory 3a will be reported
using the format reflected in Attachment 1, "AFOSI Illicit Drug Market
Assessment," AFOSI Form 161. See HQ AFOSI/IVG Crime Information Report
79-1 for detailed guidance concerning the computing and reporting of drug data.
(2) Information responsive to interrogatory 3b will be reported
using the format reflected in Attachment 2, "AFOSI Report of Illicit Drug
Trafficking," AFOSI Form 165. Conduct thorough debriefings to ensure that the
report has sufficient data to make it a meaningful measure of trafficking.
Approved For Release 2007/03/09 :. CIA-RDP83M00171 R001500010012-8
 Approved For Release 2007/03/09 : CIA-RDP83M00171 R001500010012-8
(3) Information responsive to interrogatory 3c also will be reported
using the format reflected in Attachment 2.
c. Report Timing:
(1) AFOSI Illicit Drug Market Assessments will be reviewed by the
preparing AFOSI unit at least monthly. Whenever there is an appreciable
change in the type of drugs being abused, local availability, or weight, value or
purity of drugs being encountered, an updated'. report will 'be prepared.
Revalidated copies of the assessment" will be sent to all distributees on a
quarterly basis. A case type 456 number may be assigned to transmittal
documents.
(2) Reports on Illicit Drug Trafficking will be submitted as soon as
sufficient data is collected to provide meaningful information concerning
planned (known or alleged) or actual incidents. A. case type 456 number may be
assigned to these reports.
5. SPECIALIZED DRUG ABUSE COLLECTIONS. Occasionally, AFOSI field
units receive requests for recurring support of the collection requirements of
other US agencies. For example, the Ambassador's drug abuse advisor or the
local Drug Enforcement Administration (DEA) representative may request
AFOSI to provide copies of periodic drug threats estimates prepared by host
government agencies with whom AFOSI is the primary US point of liaison.
When this type of tasking occurs, advise HQ AFOSI/IVGS of the request. Upon
approval, reports responsive to these requests may be made using the case type
456 numbering system. Districts may immediately honor one time requests for
support of this type and assign a 456 number, but should advise IVG of the
reason for the report when they transmit the material to HQ AFOSI.
6. SUSPENSE: This CR will remain in effect for a period of one year.
7. DISTRIBUTION: As prescribed in AFOSIR 124-24, ensure that copies are
sent to other AFOSI districts which have an interest in the reported
information. AFOSI Illicit Drug Market Assessments also should be provided to
USAF Drug and Alcohol Abuse Control Committees.
FOR THE COMMANDER
2 Atch
HUGH W. BARBER, Jr., Lt Col, USAF I. AFOSI Illicit Drug Market
Asst Director of Criminal Investigations ? Assessment
2. AFOSI Report of Illicit
Drug Trafficking
Approved For Release 2007/03/09 : CIA-RDP83M00171R001500010012-8